Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.
Overview
As virtual care evolves, choosing between Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) depends on whether you prefer explosive growth in consumer subscriptions or established, large-scale institutional healthcare partnerships.
Hims & Hers focuses on direct-to-consumer wellness solutions for specific conditions, such as hair loss and weight management. Teladoc provides a comprehensive virtual care platform for employers and health plans. While both lead in digital health, their paths to profitability and market strategies represent very different investment opportunities for 2026.
Details
Hims & Hers operates a direct-to-consumer digital health platform within the broader healthcare stocks category. It provides personalized treatment plans for hair care, mental health, and weight loss, serving nearly 2.6 million subscribers as of Q1 2026. The company is currently scaling its operations through the pending acquisition of Eucalyptus and recently secured a $400 million receivables facility with JPMorgan Chase (NYSE:JPM) to support its pharmacy operations.
Source
Originally published at www.fool.com.